In this issue: NIDCR Major Announcement: Save the Date!  Mark your calendar for Tuesday, December 21, at 1pm for a major webcast announcement from NIDCR. Look for log-in instructions, coming in a separate NIDCR email next week. |  NIDCR welcomed Jennifer Webster-Cyriaque, DDS, PhD, as the institute's new deputy director on December 6. Prior to joining NIDCR, Webster-Cyriaque served as a faculty member for 21 years at the University of North Carolina (UNC) schools of dentistry and medicine, where she practiced dentistry and studied the role of viruses like HIV and herpes simplex virus in oral lesions and cancers. She received her bachelor's and DDS degrees from the University at Buffalo and her doctorate from UNC. |  Capt. Renee Joskow, DDS, MPH, a dentist and medical epidemiologist, joined NIH as the senior advisor to the NIDCR director on October 24. She shared elements of her professional journey and discussed her new role in a Q&A format. Prior to NIDCR, Joskow served as the chief dental officer at the Health Resources and Services Administration, where she led oral health initiatives and collaborated with stakeholders and colleagues. She earned her DDS and master's in public health from Columbia University and serves in the US Public Health Service Commissioned Corps. |  David Julius, PhD, of UC San Francisco, and Ardem Patapoutian, PhD, of Scripps Research Institute, won the Nobel Prize in physiology or medicine on October 4 for their discoveries of thermal and mechanical receptors. The discoveries provided a foundation for understanding pain and proprioception, offering new opportunities to identify therapeutic targets. Both scientists received NIDCR funding in support of their winning research. |
Back to top
 After 12 years of service, Francis S. Collins, MD, PhD, will step down as the director of NIH by the end of 2021. During his tenure under three US presidents, Dr. Collins established bold initiatives to tackle some of the most pressing health issues facing the nation, including Alzheimer's disease, cancer, opioid use disorder, rare diseases, and the COVID-19 pandemic. He has also bolstered policies and activities to address workforce diversity, equity, and inclusion. Dr. Collins will continue to lead his research laboratory at NIH's National Human Genome Research Institute. |  NIH and FDA have partnered with 10 pharmaceutical companies and five non-profit organizations to launch the Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership program. BGTC aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of the 25-30 million Americans with rare diseases. NIDCR is one of nine NIH institutes and centers participating in the program. |  To support large-scale studies on the long-term effects of COVID-19, NIH awarded nearly $470 million to build a national study population of tens of thousands of diverse research volunteers. The award from the NIH REsearching COVID to Enhance Recovery (RECOVER) Initiative will support more than 100 researchers at more than 30 institutions. |  NIH is investing about $74.5 million over five years to advance data science, catalyze innovation, and spur health discoveries across Africa. The Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) program will establish a data science research and training network across the continent. The 19 awards issued under DS-I Africa were supported in part by NIDCR and other NIH institutes, centers, and offices. The program aims to use data science to develop solutions to the continent's most pressing public health problems. |  Disadvantaged populations experience higher rates of certain diseases and more negative health outcomes. To support bold new research ideas that focus on interventions to address these issues, NIH has awarded 11 grants through the Common Fund's Transformative Research to Address Health Disparities and Advance Health Equity initiative. The awards, totaling $58 million over five years, will be administered by NIDCR on behalf of NIH. |  To study senescent cells, a type of rare and non-dividing cells that plays both positive and negative roles in biological processes, NIH's Common Fund launched the Cellular Senescence Network program. The program aims to identify and characterize senescent cells across the body, in various states of human health, and across the lifespan. A deeper understanding of senescent cells could lead to therapies that encourage the cells' beneficial effects while suppressing tissue-damaging effects. |  Among adults ages 19 to 22, the use of vaped marijuana and vaped nicotine leveled off in 2020 after sharp yearly increases since 2017, according to survey results from the Monitoring the Future study, funded by the National Institute on Drug Abuse. Marijuana use in general reached a historic high, but cigarette smoking continued to drop, the researchers found. | Back to top  Scientists in the lab of NIDCR's Kelly Ten Hagen, PhD, have found an enzyme process in cells that may limit the infectivity of SARS-CoV-2 by adding a bulky sugar molecule that reduces the activation of the spike protein. Mutations in the alpha and delta variants seem to overcome this effect, potentially boosting the virus's ability to spread. The knowledge could inform future efforts to develop new interventions. |  NIDCR-funded researchers demonstrated the feasibility of developing a color-changing "smart" mask to detect viruses like SARS-CoV-2 in wearers' saliva. The masks could one day be used to monitor infection and prevent outbreaks, especially in group settings like nursing homes, rehab facilities, schools, and assembly lines. The project is part of NIH's Rapid Acceleration of Diagnostics Radical (RADx-rad) initiative. |  A research team led by NIDCR scientist Mark Hoon, PhD, identified an immune substance called oncostatin M (OSM) that sensitizes and enhances the activity of itch-sensing neurons. In a mouse model of chronic itch, scratching was virtually eliminated by blocking OSM activity, suggesting a therapeutic strategy for persistent itchy skin conditions like psoriasis. |  In a recent study funded in part by NIDCR, researchers found that massage therapy performed by a robotic device helped heal severely injured muscles in mice by clearing immune cells from the tissue. The finding adds to evidence that mechanical therapies can aid tissue regeneration. | Back to top Johns Hopkins University - November 18, 2021 University of Pittsburgh - November 3, 2021 University of Pennsylvania - October 25, 2021 Harvard University - October 6, 2021 University of Utah - September 21, 2021 University of Pennsylvania - September 7, 2021 University of Massachusetts Amherst - August 30, 2021 - Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)
Expiration Date: 02/03/2024 - Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
Expiration Date: 04/19/2024 - Pre-application: Opportunities for Collaborative Research at the NIH Clinical Center (X02 Clinical Trial Optional)
Expiration Date: 12/14/2023 - Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed)
Expiration Date: 06/11/2022 - HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required)
Expiration Date: 02/12/2022 - Clinical Research Education and Career Development (CRECD) Program (R25-Independent Clinical Trial Not Allowed)
Expiration Date: 12/16/2021 - NIH Blueprint for Neuroscience Research Short Courses in Neurotherapeutics Development (R25 Clinical Trial Not Allowed)
Expiration Date: 12/10/2021 - HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required)
Expiration Date: 12/10/2021 - SPARC Human Open Research Neural Engineering Technologies (HORNET) Initiative (U41 Clinical Trial Not Allowed)
Expiration Date: 01/13/2022 - Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)
Expiration Date: 06/22/2024 - Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)
Expiration Date: 06/22/2024 - INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Exploratory/Developmental Research Grant Award (R21 Clinical Trial Not Allowed)
Expiration Date: 11/04/2022 - Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)
Expiration Date: 09/10/2024 - Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) Expiration Date: 12/12/2023
- NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Expiration Date: 05/08/2024 - Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
Expiration Date: 06/21/2024 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
Expiration Date: 09/08/2024 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)
Expiration Date: 09/08/2024 - Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))
Expiration Date: 09/08/2024 - Notice of Special Interest (NOSI): The Functional Oral Microbiome
Expiration Date: 09/07/2025 - Notice of Intent to Publish a Funding Opportunity Announcement for Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) FOA
Expiration Date: 01/01/2024 - Notice of Intent to Publish the "Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15, Clinical Trial Required)" FOA
Expiration Date: 01/01/2024 - Notice of Special Interest: SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed)
Expiration Date: 01/08/2025 - Notice of Change to Review Dates of PAR-22-054, "Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)"
Expiration Date: 02/24/2022 - Notice of Participation of the National Institute of Dental and Craniofacial Research (NIDCR) in PAR-21-287 Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional)
Expiration Date: 01/01/2024 - NIDCR Guidance on Applications for Investigator-Initiated Clinical Trials
Expiration Date: 01/01/2024 - Notice of Special Interest (NOSI): Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42, R43/R44 Clinical Trial Not Allowed)
Expiration Date: 09/05/2025 - Notice of Special Interest (NOSI): Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations
Expiration Date: 09/08/2024 Back to top Visit the NIDCR website to sign up for NIDCR News. Back to top |
No comments:
Post a Comment